Meta-Analysis
doi: 10.3109/07357907.2011.621913.
The hormonal receptor status in breast cancer can be altered by neoadjuvant chemotherapy: a meta-analysis
Affiliations
- PMID: 22011281
- DOI: 10.3109/07357907.2011.621913
Item in Clipboard
Meta-Analysis
The hormonal receptor status in breast cancer can be altered by neoadjuvant chemotherapy: a meta-analysis
Cancer Invest.
2011 Nov.
Abstract
Recently, several studies have published conflicting results on the alteration of biomarkers after neoadjuvant chemotherapy for breast cancer. This meta-analysis aims to evaluate the effects of neoadjuvant chemotherapy on biomarker status in breast cancer utilizing eligible studies identified through MEDLINE. This pooled analysis has demonstrated a significant change in estrogen receptor (p = .016) and progesterone receptor (p < .001) status before and after chemotherapy. Our findings suggest that in patients receiving neoadjuvant chemotherapy, hormonal receptor status is altered by the chemotherapy, and thus, consideration should be given to reevaluation of the HR status after administration of neoadjuvant chemotherapy.
Similar articles
-
[Neoadjuvant systemic chemotherapy for patients with operable breast cancer].Zhonghua Zhong Liu Za Zhi. 2007 Mar;29(3):161-5. Zhonghua Zhong Liu Za Zhi. 2007. PMID: 17649628 Review. Chinese. No abstract available.
-
Relationship between hormonal receptors, HER-2, p53 protein, Bcl-2, and MIB-1 status and the antitumor effects of neoadjuvant anthracycline-based chemotherapy in invasive breast cancer patients.Radiat Med. 2005 May;23(3):189-94. Radiat Med. 2005. PMID: 15940066
-
[Effects of neoadjuvant chemotherapy on estrogen and progesterone receptors and HER-2 in breast cancer].Di Yi Jun Yi Da Xue Xue Bao. 2004 Dec;24(12):1437-9. Di Yi Jun Yi Da Xue Xue Bao. 2004. PMID: 15604081 Chinese.
-
[The effect of neoadjuvant chemotherapy on estrogen and progesterone receptor expression in breast carcinoma].Zhonghua Wai Ke Za Zhi. 2005 Aug 1;43(15):1011-3. Zhonghua Wai Ke Za Zhi. 2005. PMID: 16194363 Chinese.
-
Discordances in ER, PR and HER2 receptors after neoadjuvant chemotherapy in breast cancer.Cancer Treat Rev. 2011 Oct;37(6):422-30. doi: 10.1016/j.ctrv.2010.11.006. Epub 2010 Dec 21. Cancer Treat Rev. 2011. PMID: 21177040 Review.
Cited by
-
Comprehensive evaluation of the relationship between biomarker profiles and neoadjuvant chemotherapy outcomes for breast cancer patients.Diagn Pathol. 2024 Mar 20;19(1):53. doi: 10.1186/s13000-024-01451-y. Diagn Pathol. 2024. PMID: 38509525 Free PMC article.
-
Irreversible inhibition of estrogen receptor α signaling and the emergence of hormonal resistance in MCF7 breast cancer cells induced by DNA damage agents.Biomed Rep. 2024 Jan 19;20(3):42. doi: 10.3892/br.2024.1727. eCollection 2024 Mar. Biomed Rep. 2024. PMID: 38343657 Free PMC article.
-
Estrogen receptor-negative/progesterone receptor-positive breast cancer has distinct characteristics and pathologic complete response rate after neoadjuvant chemotherapy.Diagn Pathol. 2024 Jan 4;19(1):5. doi: 10.1186/s13000-023-01433-6. Diagn Pathol. 2024. PMID: 38178166 Free PMC article.
-
Clinical implications of receptor conversions in breast cancer patients who have undergone neoadjuvant chemotherapy.Breast Cancer Res Treat. 2023 Jul;200(2):247-256. doi: 10.1007/s10549-023-06978-0. Epub 2023 May 26. Breast Cancer Res Treat. 2023. PMID: 37233961 Free PMC article.
-
The changes of subtype markers between first and second primary breast cancers.Cancer Med. 2023 Jun;12(12):13649-13660. doi: 10.1002/cam4.5979. Epub 2023 Apr 25. Cancer Med. 2023. PMID: 37096879 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
